Pharmafile Logo

Breaking Down the Barriers to Effective Treatment of Hepatitis C in Latin America

August 25, 2015 | HCV, Latin America, hepatitis C 

Published in eyeforpharma June 9 by Rachel Howard and Raquel Nunez.

If left untreated, hepatitis C leads to chronic health problems putting a huge strain on national healthcare resources.

During the course of my working life, hepatitis C is one of the therapy areas in which I have seen the most dramatic advances in terms of treatment.  It is definitely one of pharma’s success stories. It has experienced rapid evolution from interferon- and ribavirin-based treatment in 1998, through pegylated interferon-based regimens and protease inhibitors and on to the recent wave of direct-acting antiviral therapies available today. It would not be an exaggeration to say that these interferon-free treatment regimens, with high efficacy (Sustained Virological Response (SVR) rates approaching 100%), minimal side effects and short treatment durations, have the potential to revolutionize the treatment of hepatitis C.

This article considers a more complex reality; how the availability of such exciting new treatments does not necessarily result in a treatment “revolution” in many emerging markets. Specifically, I will explore this in the context of the interesting example of Latin America. 

Read the full article http://www.researchpartnership.com/news/2015/06/breaking-down-the-barriers-to-effective-treatment-of…

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Understanding the chronic disease patient journey in emerging markets

In this paper, we will explore the chronic disease patient journey in emerging markets and provide you with the insights you require to identify the key inflection points in these...

Infographic: Keeping tracking on track

Our best practice approach to tracking studies.

Telehealth Research

The remote exchange of data between patients and their clinician

Case Study: Understanding the patient journey and addiction treatment pathways

Our client had previously conducted some research and knew that a large proportion of target patients also had addiction issues. They wanted to know more about addiction treatment pathways and...

Research Partnership has published a new Living with Chronic Pain market report for 2016

Chronic pain is defined as pain lasting longer than 6 months and affects 100 million Americans. Living with Chronic Pain is a quantitative study conducted online amongst 390 US patients...

Nutraceuticals: Rich in Potential

Published in eyeforpharma October 2016 by Marc Yates

Case Study: Qualitative research with payers in low and middle income countries

Our client wanted to understand in detail the usage decision drivers, triggers and processes for a high-cost innovative Acute Heart Failure (AHF) drug used in the acute emergency setting in...

Case study: Leveraging Market Research Data to Inform Healthcare Providers and the Community

Our client wanted to understand why uptake of HPV vaccination in the Asia-Pacific region was limited.  In order to help increase uptake, they wanted to publish the market research findings...

Towards a culture of evaluation and evidence-based decision making in global health

Reflections on THET Conference 2016: Evidence, Effectiveness & Impact